GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » EPS (Diluted)

Medivir AB (Medivir AB) EPS (Diluted) : $-0.03 (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Medivir AB EPS (Diluted)?

Medivir AB's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03.

Medivir AB's EPS (Basic) for the three months ended in Dec. 2023 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03.

Medivir AB's EPS without NRI for the three months ended in Dec. 2023 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03.

During the past 3 years, the average EPS without NRIGrowth Rate was -7.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 28.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Medivir AB's highest 3-Year average EPS without NRI Growth Rate was 118.50% per year. The lowest was -51.00% per year. And the median was 15.50% per year.


Medivir AB EPS (Diluted) Historical Data

The historical data trend for Medivir AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB EPS (Diluted) Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.44 -0.17 -0.13 -0.15 -

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 - - -

Competitive Comparison of Medivir AB's EPS (Diluted)

For the Biotechnology subindustry, Medivir AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's PE Ratio falls into.



Medivir AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Medivir AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.708-0)/55.7242
=-0.16

Medivir AB's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.971-0)/55.7246
=-0.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (OTCPK:MVRBF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Medivir AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Medivir AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.